Summary
73 / 100 · Bulios Score
What speaks for it
- Out of every 100 JPY of revenue, 15 JPY is left as net profit.
- It holds more cash than debt: ¥218.1B against ¥116.3B.
- Revenue grew by 10% a year over the last 3 years.
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share fell by 13% a year over the last 3 years.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensivePrice against the Bulios Fair Price
P/E against the industry (Drug Manufacturers - General)
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 13.5 JPY for 1 JPY of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (JPY)
Diluted EPS (JPY)
- Analyst estimate
Revenue grew by 11% a year over 5 years. Over the last 3 years it grew by 10% a year. For the next fiscal year analysts expect revenue to grow by 5.4%. Earnings per share fell by 13% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 JPY of revenue goes
- Cost of sales 26 JPY
- Research and development 28 JPY
- Sales and administration 23 JPY
- Taxes and other 6.9 JPY
- Net profit 15 JPY
Net profit, industry median (Drug Manufacturers - General) 14 JPY
Out of every 100 JPY of revenue, 15 JPY is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
High, at risk- Yield
- 7.10%
- Paid out of profit
- 96%
You receive $0.33 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Mildly negative- Buy 0
- Hold 0
- Sell 2
No analyst has published a price target.
0.0% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.